Added 3 months ago Drug news

Positive results from three phase III studies of roxadustat for anemia in patients with chronic kidney disease. FibroGen + AstraZeneca

FibroGen, Inc. announced that roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity (HIF-PHI), met all primary efficacy endpoints in...

Added 4 months ago Drug news

Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoints for the treatment of patients with anaemia in chronic kidney disease . AstraZeneca + FibroGen

AstraZeneca announced that the Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoints for the...

Added 5 months ago Drug news

FDA approves expended label for Promacta to include first-line treatment for adults and pediatric patients two years and older with severe aplastic anemia.-Novartis

Novartis announced that the FDA has expanded the label for Promacta (eltrombopag) to include first-line treatment for adults and pediatric...

Benzodiazepine-associated delirium in critically ill adults.

The association between benzodiazepine use and delirium risk in the ICU remains unclear.

Added 1 year ago

Sedation depth and long-term mortality in mechanically ventilated critically ill adults: a prospective longitudinal multicentre cohort study.

To ascertain the relationship among early (first 48 h) deep sedation, time to extubation, delirium and long-term mortality.

Added 1 year ago

Early intensive care sedation predicts long-term mortality in ventilated critically ill patients.

Choice and intensity of early (first 48 h) sedation may affect short- and long-term outcome.

Added 1 year ago